GSK, Cambridge researchers join hands in gene project

In an innovative new research pact, scientists from the Medical Research Council in Cambridge and GlaxoSmithKline will collaborate on new work to identify the genetic causes of diseases. Under the deal, both of the groups will invest 1 million sterling into the research as they explore new disease targets and biomarkers. The pact also allows molecular scientists to explore each other's databases.

"It's a question of scale. We need to increase the scale of the studies and in the case of the work with GSK, it's bringing together larger numbers of cohorts," Professor Nick Wareham at the MRC Epidemiology Unit in Cambridge tells Business Weekly.

- check out the article from Business Weekly

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.